BACKGROUND: Treatment of stage IIB bulky @entity978 ( @entity978 ) is controversial, with treatment varying by institution. We evaluated @entity1 with IIB bulky disease treated with combined-modality therapy at our institution by describing their long-term outcomes. @entity1 AND METHODS: We identified 149 consecutive @entity1 with stage IIB bulky @entity978 treated between 1971 and 2012. Clinical, pathologic, and treatment characteristics were extracted from medical records. Actuarial overall survival (OS) and relapse-free survival (RFS) were calculated by the Kaplan-Meier method. Independent factors associated with these outcomes were identified by a multivariate Cox regression model. Outcomes were further compared against comparison groups of both advanced-stage and stage IIB @entity1 treated between 1971 and  2009. RESULTS: The 8-year OS rate for @entity1 with stage IIB bulky disease who received combined-modality ABVD ( @entity632 , @entity1732 , @entity5713 , @entity2699 ) and radiation was 88.8%; the 8-year RFS rate was 76.8%. On multivariate analysis, age  < 40 years (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.14-0.57; P  = .001), receipt of ABVD (vs. MOPP [ @entity3700 , @entity1891 , @entity4174 , @entity229 ]; HR, 0.32; 95% CI, 0.10-0.88; P  = .028), and radiation dose  >=  30.1 Gy (HR, 0.25; 95% CI, 0.11-0.65; P  = .006) were associated with improved OS. @entity299 (n  = 11) and secondary @entity5 (n  = 11) only occurred in @entity1 treated before 1995. A subgroup analysis demonstrated significantly improved survival in IIB bulky versus advanced-stage @entity1 (8-year OS, 73.4% vs. 57.4%; P  = .008). Improved outcomes in @entity1 with in IIB bulky disease were especially evident in the modern era (> 1995; P  = .004). CONCLUSION: @entity1 with stage IIB bulky @entity978 had excellent outcomes after combined-modality therapy. Treatment strategies have changed substantially over time, with concomitant improvements in disease outcomes and long-term @entity137 .

Outcomes After Chemotherapy Followed by Radiation for XXXX With Bulky Disease.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity3700 :: ('MESH:D008466', 'Chemical') :: ['mechlorethamine'] @entity4174 :: ('MESH:D011344', 'Chemical') :: ['procarbazine'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity2699 :: ('MESH:D003606', 'Chemical') :: ['dacarbazine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin'] @entity299 :: ('MESH:D006331', 'Disease') :: ['Cardiac events'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HL', 'Hodgkin lymphoma'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity978 :: (MESH:D006689,Disease) :: ['Stage IIB Hodgkin Lymphoma']
